(TheNewswire)
Thetford Mines, Quebec – TheNewswire - March 21, 2024 – KDA Group Inc. (TSXV:KDA) (“ KDA ” or the“ Corporation ”) is pleased to announce an update in the development anduse of its Adherize+ platform. With the aim of assisting and improvingthe follow-up of hormone-dependent breast cancer patients taking oralCDK 4/6 inhibitor therapy, the Corporation, through its Adherize+platform, will develop the monitoring and follow-up algorithm forthese patients in collaboration with oncology physicians andpharmacists.
CDK 4/6 inhibitors are proven effective treatments formany hormone-dependent breast cancers in the adjuvant (preventive) ormetastatic (palliative) setting, in combination with an aromataseinhibitor. Adherize+ will be able to maximize real-time treatmentmanagement between healthcare providers and patients receiving thisdrug, enabling direct and active communication in monitoring adherenceand any adverse effects that may occur during the prescribed course oftreatment.
This new relationship created by Adherize+ will bringpeace of mind to every patient, who will be able to access rapidcommunication and a wealth of information to reassure and support themin following and respecting their treatment according to recognizedmedical and therapeutic recommendations, for example automatic dosageadjustments based on laboratory tests performed.
Canadian and Quebec epidemiological data
It is estimated that in 2023, 239,100 Canadians will bediagnosed with cancer, and 86,700 will die from it. Lung and bronchialcancer, breast cancer, prostate cancer and colorectal cancer areexpected to account for 46% of new cancer diagnoses. Breast canceraccounts for 25.6% of newly diagnosed cancers among women. 1
In 2023, the Canadian Cancer Society estimated that7,065 new cases of breast cancer would be diagnosed in Quebec (29,700in Canada), and that 1,415 deaths would be recorded (5,500 in Canada).The majority of breast cancers are hormone dependent. Breast cancer isthe most frequently diagnosed malignant tumor in women, and the secondleading cause of cancer-related death in Quebec and Canada. Canadianwomen are more likely to develop breast cancer than any other cancer:it is estimated that one in 8 women will be diagnosed with breastcancer in her lifetime. 1
Adherize+ therefore becomes a simple and logicalsolution for any healthcare professional to ensure real-timemonitoring of all their patients.
“Many new anti-cancer molecules are now administeredorally, requiring rigorous outpatient monitoring. The oral route doesnot rule out potentially serious side effects. The number of patientsto be treated is constantly increasing. In a context of manpowershortage and increasing complexity of oncology treatments, we need tobe innovative and find technological solutions to treat our patientsefficiently and safely. The planned development of Adherize+ shouldenable us to achieve these objectives, in the best interests of ourpatients,” said Dr. Éric Poirier, Oncology Surgeon, practicing inthe Clinique des Maladies du Sein at the Centre HospitalierUniversitaire de Québec (CHU de Québec-Université Laval). Dr.Poirier is a shareholder of the Corporation.
ABOUT KDA GROUP
KDA Group is a leader in technological innovations andspecialized software solutions (SAAS – Software as a Service) forthe healthcare professionals’ market. KDA is a corporation thatoffers quality products and has a respected expertise among thevarious stakeholders in the pharmaceutical and medical sectors. Thetechnology products developed by KDA aim, among other things, toaccelerate the healthcare’s digital transformation, and areavailable for the Canadian and international markets. Additionalinformation about the Corporation is available at www.kdagroup.com and onSEDAR+ at www.sedarplus.ca .
- 30 -
REFERENCE
1- Canadian Cancer StatisticsAdvisory Committee 2023, in collaboration with the Canadian CancerSociety, Statistics Canada and the Public Health Agency ofCanada.
CAUTION REGARDINGFORWARD-LOOKING STATEMENTS
This press release from KDA Groupcontains forward-looking statements. Forward-looking statements aretypically identified by the words assumption , goal , guidance , objective , outlook , strategy , target, and other similar expressions, or futureor conditional verbs such as aim , anticipate , believe , predict , could , expect , intend , may , plan , seek , should , strive, and will . By their nature, forward-looking statements require us to makeestimates and assumptions and express opinions based on currentconditions and anticipated developments, as well as other factors thatManagement may deem appropriate under the circumstances. There isinherent uncertainty and significant risk in these estimates,assumptions, and opinions, particularly of a commercial, economic, andcompetitive nature, and they are therefore subject to change. KDAGroup cannot guarantee that these estimates, assumptions, and opinionswill prove to be accurate.
Neither the TSX Venture Exchange norits Regulation Services Provider (as that term is defined in thepolicies of the TSX Venture Exchange) accepts responsibility for theadequacy or accuracy of this press release.
INFORMATION
Marc Lemieux, Chief Executive Officer
514 622-7370
Copyright (c) 2024 TheNewswire - All rights reserved.